TherapeuticsMD director Cooper Collins buys $2k in company stock By Investing.com

In a recent move that might signal confidence in the company’s prospects, Cooper C. Collins, a director at TherapeuticsMD, Inc. (NASDAQ:), has increased his stake in the firm. On August 21, Collins purchased 1,200 shares of common stock, investing a total of approximately $2,038 at a weighted average price of $1.6988 per share.

The transaction, disclosed in a regulatory filing, saw shares acquired at prices ranging from $1.685 to $1.70. Collins now holds a total of 47,922 shares in the pharmaceutical company following the purchase.

TherapeuticsMD, based in Boca Raton, Florida, specializes in pharmaceutical preparations and has been a subject of investor interest. The purchase by Collins could be perceived as a positive indicator by the market, as insider transactions are often closely watched for insights into a company’s health and future performance.

Investors and those following the company will continue to monitor insider activity for signs of where those closest to the company believe its stock is headed.

InvestingPro Insights

As investors assess the significance of Cooper C. Collins’ recent stock purchase in TherapeuticsMD, Inc. (NASDAQ:TXMD), several metrics from InvestingPro provide a broader context for evaluating the company’s financial health and market valuation. The director’s increased investment comes at a time when TherapeuticsMD holds a market capitalization of approximately $20.41 million USD, reflecting the company’s size and market value.

One of the key InvestingPro Tips suggests that analysts are optimistic about the company’s future, predicting not only sales growth in the current year but also expecting TherapeuticsMD to achieve profitability within the same timeframe. This aligns with the director’s stock purchase, potentially indicating an insider’s belief in the company’s growth trajectory and upcoming financial turnaround.

Despite a challenging period, with revenue showing a significant decline of 98.57% over the last twelve months as of Q2 2024, the company operates with a moderate level of debt and is trading at a high revenue valuation multiple. The P/E ratio stands at -3.24, which may suggest that investors are hopeful about the company’s future earnings potential. Moreover, with a PEG ratio of 0.04, there is an indication that the market expects TherapeuticsMD’s earnings growth to outpace its P/E ratio, which could be a sign of undervaluation if the company meets or exceeds growth forecasts.

For those looking to delve deeper, InvestingPro offers additional insights, with a total of 7 InvestingPro Tips available at https://www.investing.com/pro/TXMD, which could provide further guidance on the potential investment opportunities with TherapeuticsMD. Among these tips, the company’s non-payment of dividends is highlighted, which could be relevant for investors prioritizing capital gains over income.

The recent insider purchase, coupled with the InvestingPro metrics and tips, offers a multifaceted view of TherapeuticsMD’s current position and future expectations, which investors may find valuable when considering their investment decisions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.